There is provided with a pharmaceutical composition for use in protecting a respiratory tract or a lung from damage. The pharmaceutical composition comprises trehalose or a trehalose derivative.
A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug.
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
3.
THERAPEUTIC AGENT FOR INFLAMMATORY RESPIRATORY DISEASES COMPRISING TREHALOSE
[Problem] The purpose of the present invention is to provide a therapeutic agent for inflammatory respiratory diseases, which has excellent biocompatibility. [Solution] The present invention is achieved essentially on the basis of working examples in which inflammatory respiratory diseases can be treated with trehalose or a derivative thereof. The therapeutic agent for inflammatory respiratory diseases according to the present invention comprises trehalose as an active ingredient. Therefore, it becomes possible to provide a therapeutic agent for inflammatory respiratory diseases, which has excellent biocompatibility. Particularly, the present invention can be used effectively as a therapeutic agent for bronchial asthma.
[Problem] To provide a therapeutic and prophylactic agent for keloid or hypertrophic scar. [Solution] A therapeutic and prophylactic agent for keloid or hypertrophic scar, said agent comprising trehalose as the active ingredient. The aforesaid prophylactic agent for keloid or hypertrophic scar can be preferably used as an agent which is to be administered to a surgical site after surgery. As Example shows, the agent according to the present invention can effectively cure keloid or hypertrophic scar and prevent the same due to trehalose that is contained therein as the active ingredient.
Disclosed is a respiration-assisting tube whereby tissue damages in vivo can be prevented and, as a result, inflammatory reactions and infections can be avoided. The respiration-assisting tube is developed based on the finding that adhesion of cells to a respiration-assisting tube can be inhibited by coating the respiration-assisting tube with a polymer containing 2-methacryloyloxyethyl phosphorylcholine (MPC). Also, the respiration-assisting tube is developed based on the finding that, by coating a respiration-assisting tube with a polymer containing MPC, mucosa peeling and tissue damages, which occur after using the respiration-assisting tube, can be prevented and, as a result, inflammatory reactions can be avoided.
B05D 1/18 - Processes for applying liquids or other fluent materials performed by dipping
B05D 3/00 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
B05D 7/00 - Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
C09D 143/02 - Homopolymers or copolymers of monomers containing phosphorus
A61L 17/14 - Post-treatment to improve physical properties
[Problem] The objective of the present invention is to provide a flexible and highly stretchable lattice. Also, the objective of the present invention is to provide a lattice that, by adjusting the modulus of elasticity by means of the structure of the material thereof, can be caused to conform to the modulus of elasticity of a material to be composited. [Solution] The lattice structure (100) includes: a plurality of lattice bridges (10) that curve or bend in an S-shape; and a plurality of lattice points at which the ends of three lattice bridges (10) from among the plurality of lattice bridges (10) are joined. Also, the plurality of lattice bridges (10) and the plurality of lattice points (20) demarcate a plurality of lattice openings (30). Here, each of the lattice openings (30) is demarcated by means of being enclosed by six lattice bridges (10) and six lattice points (20) among the plurality of lattice bridges (10) and the plurality of lattice points (20). As a result, the lattice structure (100) is flexible and has high stretchability.
Disclosed is an artificial bone material having controlled calcium ion elution, which does not induce cytotoxicity or any inflammatory response. It is found that the elution of a calcium ion from an artificial bone material for transplantation which contains a calcium-containing substance can be prevented effectively by subjecting the carrier to a surface treatment or adding a surface-treating agent to the carrier. It is also found that the induction of cytotoxicity can be prevented and the induction of an inflammatory response can also be prevented by using the above-mentioned carrier having controlled calcium ion elution.
Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
9.
ARTIFICIAL BONE CONSTRUCTING UNIT AND ARTIFICIAL BONE CONSTRUCTING SYSTEM
Provided are an artificial bone constructing unit which is capable of being built into a free shape according to build-up design, and effectively guiding bone replacement, and an artificial bone system. Specifically disclosed are an artificial bone constructing unit and an artificial bone constructing system, wherein in principal, the artificial bone constructing unit which constructs an artificial bone is so made into a block shape that when blocks are assembled, continuous holes through a plurality of blocks are formed.
Disclosed is a respiration-assisting tube whereby tissue damages in vivo can be prevented and, as a result, inflammatory reactions and infections can be avoided. The respiration-assisting tube is developed based on the finding that adhesion of cells to a respiration-assisting tube can be inhibited by coating the respiration-assisting tube with a polymer containing 2-methacryloyloxyethyl phosphorylcholine (MPC). Also, the respiration-assisting tube is developed based on the finding that, by coating a respiration-assisting tube with a polymer containing MPC, mucosa peeling and tissue damages, which occur after using the respiration-assisting tube, can be prevented and, as a result, inflammatory reactions can be avoided.
The object of the present invention is to offer a high strength hydrogel and a process for producing the same. Another object of the present invention is to offer a process for producing hydrogels with different rates of dissolution. The basis of the present invention is the discovery that by adjusting the pH of the solution, the ionic strength in the solution and the buffer concentration in the solution, it is possible to produce a high strength hydrogel. The basis of the present invention is also the discovery that by homogeneously dispersing two tetrabranched compounds and then polymerizing the two tetrabranched compounds, it is possible to produce a high strength hydrogel which has a uniform macromolecular network structure.
Provided is an NSAIDs-induced gastrointestinal mucosal disorder alleviator for alleviating gastrointestinal mucosal disorders attributable to NSAIDs. Agents prepared by mixing a sugar into NSAIDs have been known as agents for alleviating gastrointestinal mucosal disorders attributable to NSAIDs. However, the agents prepared by mixing a sugar into NSAIDs have not achieved a sufficient effect in alleviating gastrointestinal mucosal disorders. The inventors discovered a novel NSAIDs-trehalose intermolecular compound. The novel intermolecular compound is capable of markedly inhibiting gastrointestinal mucosal disorders induced by NSAIDs.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided is a method for producing a cartilage cell not undergoing hypertrophic differentiation and a cartilage cell sheet not undergoing hypertrophic differentiation which are to be used for repairing a damaged cartilage site due to, for example, arthrosis deformans. Also provided are a cartilage cell sheet which can promote cartilage regeneration and a method for producing the same. Also provided is an agent which promotes cartilage regeneration. It is found out that dedifferentiated cartilage cells can be redifferentiated by administering a compound represented as a thienoindazole derivative (hereinafter abbreviated as TM) to the dedifferentiated cartilage cells or undifferentiated mesenchymal cells. Also, it is found out that TM induces the initial differentiation of a cartilage and does not promote the hypertrophic differentiation of cartilage cells. Moreover, it is found out that TM enhances the expression of type 2 collagen that is a cartilage differentiation marker.
An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction.
The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
Provided is a bone defect filler capable of promoting the osteogenetic effect of a growth factor such as PRP. It is anticipated that, in the combined use of a bone defect filler with a growth factor such as PRP, the osteogenetic effect of PRP might be impaired because of the adsorption of PRP by the bone defect filler. This adsorbing effect of the bone defect filler is inhibited basically by using a capping agent. Since the adsorbing effect of the bone defect filler is thus inhibited, PRP can exert the osteogenetic effect thereof in the case of using the bone defect filler together with PRP.
Disclosed is an artificial bone material having controlled calcium ion elution, which does not induce cytotoxicity or any inflammatory response. It is found that the elution of a calcium ion from an artificial bone material for transplantation which contains a calcium-containing substance can be prevented effectively by subjecting the carrier to a surface treatment or adding a surface-treating agent to the carrier. It is also found that the induction of cytotoxicity can be prevented and the induction of an inflammatory response can also be prevented by using the above-mentioned carrier having controlled calcium ion elution.
The objective is to provide an alignment-setting instrument for surgical tools, which can align accurately, and a manufacturing method thereof. The above problem is solved with a method for manufacturing alignment-setting instruments for surgical tools and with a setting instrument. The method is a manufacturing method for surgical tool alignment-setting instruments which comprises a process for manufacturing a bone model, a process for applying the above setting instrument to the bone model before molding and making the shape of the setting instrument a suitable shape and a process wherein an alignment guide is provided on the setting instrument and the setting instrument is hardened.
[PROBLEMS] To provide: a therapeutic or prophylactic agent for vasoconstriction; a therapeutic or prophylactic agent for cerebral vasoconstriction; a therapeutic or prophylactic agent for arterial vasoconstriction; and a therapeutic or prophylactic agent for cerebral ischemia or cerebral infarction. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic or prophylactic agent for vasoconstriction, cerebral ischemia or cerebral infarction, which comprises trehalose as an active ingredient; and others. A medicinal agent comprising trehalose can prevent the narrowing of a blood vessel or the thickening of an inner membrane or a media and therefore can prevent or treat vasoconstriction or a vasoconstriction-related disease.
[PROBLEMS] To provide a bone defect filler having controlled release of a medicinal agent such as a growth factor, and to provide a release-controlled carrier having controlled release of a medicinal agent. [MEANS FOR SOLVING PROBLEMS] It is found that, in a bone defect filler having a medicinal agent contained therein, the adsorption of the medicinal agent to the bone defect filler can be controlled by inactivating a functional group in the bone defect filler which can strongly bind to the medicinal agent with a blocking agent, and therefore it becomes possible to control the release of a growth factor or the like from the bone defect filler. Specifically disclosed are: a bone defect filler or a release-controlled carrier which comprises a calcium-containing substance such as hydroxyapatite, carbonate apatite, fluorapatite, chlorapatite, β-TCP and α-TCP, a blocking agent for the calcium-containing substance such as serine and dextran, and a medicinal agent; and others.
[PROBLEMS] To provide a process for producing a bone filler, in which a bone filler for filling a cavity of bone defect can be produced with high precision. [MEANS FOR SOLVING PROBLEMS] There is provided a process for producing a bone filler, fundamentally including the bone model fabrication step (step 1) of fabricating a bone model; the image forming agent filling step (step 2) of filling an image forming agent into a cavity of bone defect of the bone model obtained in the bone model fabrication step; and the bone filler production step (step 3) of producing a bone filler for filling the cavity of bone defect on the basis of the image forming agent having filled the cavity of bone defect of the bone model in the image forming agent filling step.
A61L 27/00 - Materials for prostheses or for coating prostheses
21.
FIGURE-FORMING COMPOSITION, PROCESS FOR PRODUCTION OF FIGURES IN THREE DIMENSIONS BY USING THE COMPOSITION AND PROCESS FOR PRODUCTION OF THREE-DIMENSIONAL STRUCTURES
[PROBLMES] To provide a figure-forming composition which enables the initiation of hardening even with a small amount of water and can attain a prescribed hardness and which is suitable particularly for the production of three-dimensional living body models for operative training by a rapid prototype process; and figures in three dimensions and three-dimensional structures, made by using the composition. [MEANS FOR SOLVING PROBLEMS] A figure-forming composition comprising a calcium material such as hemihydrate gypsum and polyvinyl alcohol resin, wherein the content of the polyvinyl alcohol resin is 2 to 8 parts by weight per 100 parts by weight of the total of the calcium material and the resin.
C04B 28/14 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing calcium sulfate cements
C04B 24/26 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
B28B 1/30 - Producing shaped articles from the material by applying the material on to a core, or other moulding surface to form a layer thereon
B29C 67/00 - Shaping techniques not covered by groups , or
C08K 3/00 - Use of inorganic substances as compounding ingredients
C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
22.
PROCESS FOR PRODUCING BONE GRAFTING MATERIAL, BONE GRAFTING MATERIAL, THREE-DIMENSIONAL SUPPORT FOR CELL CULTURE, AND SEPARATION SUPPORT FOR CHROMATOGRAPHY
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
NEXT21 K.K. (Japan)
GAUSS K. K. (Japan)
Inventor
Tei, Yuichi
Teraoka, Kay
Suzuki, Shigeki
Shimizu, Koutaro
Takane, Katsuhisa
Abstract
A novel process for producing a bond grafting material. The process for bone grafting material production comprises: a kneading step in which a raw material comprising a calcic substance and a material comprising a binder are kneaded together; a molding step in which the mixture obtained in the kneading step is injection-molded with an injection molding machine having a mold to obtain a molding of a given shape; a binder removal (degreasing) step in which the binder contained in the molding obtained in the molding step is removed to obtain a degreased object; and a sintering step in which the degreased object after the binder removal step is heated and sintered to obtain a sinter.
The invention provides a gel-forming composition which permits on-site administration and can form a gel exhibiting a prescribed strength and sustained drug release, devices for the application thereof, and kits for medical use. A gel-forming composition which is composed of the first composition comprising a drug, the first gelling agent consisting of a compound of the general formula (I) and so on, and the first diluent and the second composition comprising the second gelling agent consisting of a compound of the general formula (I) and so on and the second diluent; and application devices and kits for medical use, which can hold the gel-forming composition: X1-(OCH2CH2)n-X2 (I) wherein X1 and X2 are each -R1COONHS (wherein R1 is C1-7 alkylene), -COR1COONHS, -NOCOR1-R2 (wherein R2 is maleimido), -R1NH2, -R1SH, or -CO2PhNO2; and n is an integer of 80 to 1000.
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
patents
